Angiotensin Metabolism

Product #

Description

Biochem/physiol Actions

Add to Cart
A4980 Abz-FRK(Dnp)P-OH trifluoroacetate salt ≥95% (HPLC), solid Substrate for ACE (Angiotensin Converting Enzyme). Internally quenched fluorogenic substrate for Real Time Fluorescent Assay.
    • A5855 Abz-LFK(Dnp)-OH trifluoroacetate salt ≥98% (HPLC), powder Abz-LFK(Dnp)-OH is an Angiotensin Converting Enzyme (ACE) fluorescent peptide substrate specific for the C domain for real time fluorescent assay (ACE, Peptidyl Dipeptidase, Kininase II, E.C. 3.4.15.1).
    • A5730 Abz-SDK(Dnp)P-OH trifluoroacetate salt ≥91% (HPLC), lyophilized powder Abz-SDK(Dnp)P-OH is an Angiotensin Converting Enzyme (ACE) fluorescent peptide substrate specific for the N domain for real time fluorescent assay (ACE, Peptidyl Dipeptidase, Kininase II, E.C. 3.4.15.1).
    • A2580 Angiotensin Converting Enzyme from porcine kidney lyophilized powder, ≥10 units/mg protein (Bradford) Removes C-terminal dipeptides from susceptible substrates, e.g., angiotensin I and bradykinin.
    • A6778 Angiotensin Converting Enzyme from rabbit lung ≥2.0 units/mg protein (modified Warburg-Christian) Removes C-terminal dipeptides from susceptible substrates, e.g., angiotensin I and bradykinin.
    • A0773 Angiotensin Converting Enzyme Inhibitor ≥95% (TLC)  
    • B0935 Benazepril hydrochloride ≥98% (HPLC), solid Benazepril is a long-acting angiotensin converting enzyme (ACE) inhibitor.
    • C4042 Captopril ≥98% (HPLC), powder Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.
    • E6888 Enalapril maleate salt powder, ≥98% (TLC) A long-acting angiotensin-converting enzyme inhibitor.
    • F1308 Fosinopril sodium ≥98% (HPLC), powder Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.
    • F7131 N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly  
    • H4884 Hippuryl-His-Leu acetate salt Substrate for angiotensin converting enzyme.
    • H1635 N-Hippuryl-His-Leu hydrate powder, ≥98% (HPLC)  
    • M0821 Moexipril hydrochloride powder, ≥98% (HPLC) Moexipril is an ACE-Inhibitor; Antihypertensive; Unlike other ACE inhibitors, prolongs QT interval leading to torsades de pointes and cardiad arrhythmia;
    • P0094 Perindopril erbumine Perindopril erbumine is an angiotensin converting enzyme (ACE) inhibitor; antihypertensive; becomes hydrolyzed in vivo to the active diacid metabolite; unlike the other ACE inhibitors, inhibits tumor growth in hepatocellular carcinoma cells due to suppression of VEGF levels; also suppresses angiotensin II production in vitro. Long-term therapy with this agent has a beneficial effect on the cerebral circulation by improving cerebral perfusion reserve in patients with previous minor stroke.
    • Q0632 Quinapril hydrochloride ≥98% (HPLC), solid Quinapril is a short-acting angiotensin converting enzyme (ACE) inhibitor.
    • Q0264 Quinaprilat hydrate ≥98% (HPLC) Quinaprilat is the active metabolite of Quinapril. It is an angiotensin converting enzyme (ACE) inhibitor, an antihypertensive used in treatment of congestive heart failure. Quinaprilat has high affinity to tissue ACE, and has been shown to improve impaired flow-dependent (endothelium-mediated) dilation (FDD) in patients with chronic heart failure compared to other ACE inhibitors with low affinity for tissue ACE.
    • R0404 Ramipril ≥98% (HPLC) Angiotensin converting enzyme (ACE) inhibitor.
    • T4827 Trandolapril ≥98% (HPLC), white powder Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.
    • Z1252 Zofenopril calcium >98% (HPLC), powder Zofenopril is a long-lasting, lipophilic ACE inhibitor. Zofenopril is also an inhibitor of PEPT2, the predominant peptide transporter in kidney and choroid plexus.